Posted by Michael Wonder on 03 Jan 2017
Two key FDA decisions to watch out for in January 2017
2 January 2017 - The drug development process is often lengthy and time-consuming and requires the utilisation of a lot of funds and resources. It may well take a drug anything between 10-12 years to be successfully developed and reach the market.
In such a scenario, key pipeline events including data readouts and regulatory updates are of paramount importance -- companies which hit the bull's eye become overnight success stories with shares even doubling or tripling on positive news while negative outcomes have an equally strong effect on the shares and failure may very well spell doom for these companies. Last year, the FDA had approved 22 drugs including Spinraza (spinal muscular atrophy), Rubraca (ovarian cancer), Exondys 51 (Duchenne muscular dystrophy), Epclusa (all six major forms of hepatitis C virus), and Zinbryta (multiple sclerosis) among others.
